Negrao, Marcelo V.

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,061

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 387

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 242

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 203

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 194

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine

Lung Cancer Treatments and MutationsHippo pathway signaling and YAP/TAZ

Cited by 177

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., Qin, K., Sujit, S. J., Lu, X., Young, E., et al. (2023) · The Lancet Digital Health

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 121

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Ricciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., Vaz, V. R., Gupta, H., Pecci, F., Barrichello, A., et al. (2022) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 112

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C -Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

Negrao, M. V., Spira, A. I., Heist, R. S., Jänne, P. A., Pacheco, J. M., Weiss, J., Gadgeel, S. M., Velastegui, K., Yang, W., Der-Torossian, H., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 85

Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer

Araujo, H. A., Pechuan-Jorge, X., Zhou, T., Do, M. T., Hu, X., Rojas Alvarez, F. R., Salvatierra, M. E., Ibarguen, H. P., Lee, R., Raghulan, R., et al. (2024) · Cancer Discovery

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 70

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Cassier, P. A., Dooms, C. A., Gazzah, A., Felip, E., Steeghs, N., Rohrberg, K. S., De Braud, F. G., Solomon, B. J., Schuler, M. H., Tan, D. S.-W., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 35

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

Negrao, M. V., Cassier, P. A., Solomon, B., Schuler, M., Rohrberg, K., Cresta, S., Dooms, C., Tan, D. S. W., Loong, H. H.-F., Amatu, A., et al. (2023) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 28

Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non–Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series

Bernstein, E., Luo, J., Wang, K., Negrao, M. V., Jänne, P. A., & Sabari, J. K. (2024) · JCO Precision Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 10

P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Negrao, M., Reuben, A., Robichaux, J., Le, X., Nilsson, M., Elamin, Y., Wu, C., Zhang, J., Landry, L. L., Roarty, E., et al. (2018) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 2

Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance

Udagawa, H., Shibata, Y., Nilsson, M. B., Nishii, K., Robichaux, J. P., Galan-Cobo, A., He, J., Poteete, A., Qian, Y., Molkentine, D., et al. (2026) · Journal of Thoracic Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 1